Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Autor:
Marthe C.J. Roex, Lisette Bogers, Esther H.M. van Egmond, Jaap Jan Zwaginga, Tanja Netelenbos, Peter A. von dem Borne, Sabrina A.J. Veld, Inge Jedema, Hendrik Veelken, Charissa Wijnands, Constantijn J.M. Halkes, J.H. Frederik Falkenburg
Publikováno v:
Cytotherapy, 23(1), 46-56. ELSEVIER SCI LTD
Background aims: To reduce the risk of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT), T-cell depletion (TCD) of grafts can be performed by the addition of alemtuzumab (ALT) "to the bag" (in vitro) before transp
Autor:
Yao Wang, Kaichao Feng, Zhiqiang Wu, Fengxia Shi, Yang Liu, Qingming Yang, Yelei Guo, Hanren Dai, Weidong Han, Chuan Tong
Publikováno v:
Cytotherapy. 22:573-580
The current clinical outcome for patients with metastatic pancreatic carcinoma (PC) remains poor. Epidermal growth factor receptor (EGFR) is detectable in PC, suggesting that EGFR is a rational target in PC. We conducted a phase I clinical trial to e
Publikováno v:
Cytotherapy. 22:16-20
Background aims Baseline platelet count has been shown to be a sensitive predictor of autologous peripheral blood progenitor cell collection yield in patients with multiple myeloma mobilized with granulocyte colony-stimulating factor (G-CSF). Patient
Autor:
Elizabeth C. Lessey-Morillon, Ross A. Marklein, Steven R. Bauer, Hannah G. Polikowsky, Katherine A. Drake, Matthew W. Klinker
Publikováno v:
Cytotherapy. 21:17-31
Background Although a preponderance of pre-clinical data demonstrates the immunosuppressive potential of mesenchymal stromal cells (MSCs), significant heterogeneity and lack of critical quality attributes (CQAs) based on immunosuppressive capacity li
Autor:
Koji Nagaoka, Akihiro Hosoi, Yasuyoshi Sato, Hirokazu Matsushita, Kazuhiko Mori, Kazuhiro Kakimi, Yasuyuki Seto, Kosuke Hirano, Koichi Yagi, Yukari Kobayashi
Publikováno v:
Cytotherapy. 23(5)
Background aims After therapy with platinum, 5-fluorouracil and taxane, no further recommended therapy is available for recurrent or metastatic esophageal cancer (r/mEC). Here the authors report two phase 1 trials of adoptive γδT-cell therapy, one
Autor:
Karl S. Peggs, Norbert Claude Gorin, Noel Milpied, Didier Blaise, Sebastian Giebel, Gilles Salles, Reinhard Marks, Patrice Chevallier, Herve Finel, William Arcese, Ariane Boumendil, Mohamed Amine Bekadja
Publikováno v:
Cytotherapy. 23(6)
Background aims: Around 50 000 autologous stem cell transplantations are done each year worldwide using cryopreserved peripheral blood stem cells (PBSCs). Cryopreservation is time-consuming and expensive. Since 2007, several retrospective studies hav
Autor:
Yaqi Yin, Li Zang, Bing Li, Jieqing Gao, Songyan Yu, Yu Cheng, Jiejie Liu, Jing Xue, Yiming Mu
Publikováno v:
Cytotherapy. 23(6)
Background aims The authors aimed to observe β-cell dedifferentiation in type 2 diabetes mellitus (T2DM) and investigate the reversal effect of umbilical cord-derived mesenchymal stem cells (UC-MSCs) on early- and late-stage β-cell dedifferentiatio
Autor:
Rebecca E. Burnham, Jamie A.G. Hamilton, Jaquelyn T. Zoine, Jamie Y. Story, Christopher B. Doering, H. Trent Spencer, Sunil S. Raikar
Publikováno v:
Cytotherapy
Engagement between the natural killer group 2, member D (NKG2D) receptor and its ligands is one of the main mechanisms used by immune cells to target stressed cells for cell death. NKG2D ligands are known markers of cellular stress and are often upre
Autor:
Maria L. Escolar, Xiaohua Chen, Zhou Fang, Wei Chen, Paul Szabolcs, Mark Vander Lugt, Memphis J. Hill
Publikováno v:
Cytotherapy
Forkhead box P3 (FOXP3)+ regulatory T cell (Treg) reconstitution after unrelated donor umbilical cord blood transplantation in chemotherapy-naive children is incompletely characterized. We studied 21 children with nonmalignant diseases receiving an i
Autor:
Durga Krishnamurthy, Hermine I. Brunner, Hilal Cevik, Stephen N. Waggoner, Seth D. Reighard, Harsha Seelamneni, David E. Ochayon, Ayad Ali
Publikováno v:
Cytotherapy
Background aims Certain therapies (e.g., daclizumab) that promote expansion of natural killer (NK) cells are associated with clinical amelioration of disease in the context of multiple sclerosis and associated mouse models. The clinical benefits are